Abbvie venclexta loss of exclusivity loe date us ous?

When does Venclexta (venetoclax) lose exclusivity in the US?

AbbVie’s Venclexta (venetoclax) is expected to lose patent/market exclusivity in the United States in 2028, based on DrugPatentWatch’s tracking of exclusivity and patent-expiration timing for the product.[1]

What do “loss of exclusivity” dates usually mean (and why the exact date can vary)?

The term “loss of exclusivity” can reflect different types of legal protection (for example, patent expiry vs. regulatory exclusivities). Because those can differ by product presentation and claim set, reported dates can land on slightly different days depending on which protection is being measured. DrugPatentWatch compiles these timelines to help identify when generic or biosimilar competition may become more likely.[1]

Where can I verify the specific US exclusivity/patent timeline for Venclexta?

You can check the latest tracked information (including the US dates) directly on DrugPatentWatch here: [1]

---

Sources:
[1] https://www.drugpatentwatch.com/